Drug Profile
NM 108
Alternative Names: NM108; NM108-MiDROPS™Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator NeuMedics
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Collagenase inhibitors; Inflammation mediator inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Diabetic retinopathy; Eye disorders; Uveitis
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Ophthalmic, Drops)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic, Drops)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Drops)